Literature DB >> 6144481

The disposition and metabolism of tiazofurin in rodents, rabbits, and dogs.

S T Arnold, H N Jayaram, G R Harper, C L Litterst, L Malspeis, J J DeSouza, A E Staubus, G S Ahluwalia, Y A Wilson, D A Cooney.   

Abstract

The pharmacokinetics and metabolism of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide) have been examined in the mouse, rat, rabbit, and dog using tritiated drug as a marker. In all four species, tiazofurin, given as a single bolus iv injection, is removed from the circulation in a triphasic manner, with a generally prolonged terminal half-life. In all cases, the mean concentration of unchanged drug prevailing during this terminal phase was well within the cytotoxic range (IC50 vs. P388 cells is 2 microM in vitro). Urinary excretion accounted for between approximately 40 and 90% of the administered dose in all four species, with only minor quantities (less than 3%) of drug-derived radioactivity detected in the feces. The metabolism of tiazofurin was examined in mice and rats: although no evidence was uncovered for hydroxylation of tiazofurin at carbon atom 5 of the thiazole ring, phosphorylation of the drug at its 5'-hydroxyl was demonstrable in nearly every organ of both species, but, liver, striated muscles, and kidney were the only tissues catalyzing the synthesis of thiazole-4-carboxamide adenine dinucleotide to any prominent degree. This synthesis did not appear to be a saturated process, even at doses as high as 8000 mg/m2. Since rodent skeletal muscle accumulated high concentrations of tiazofurin phosphates in vivo, it is suggested that musculature may serve as a reservoir for the drug, and contribute to its rather protracted terminal half-life in plasma.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6144481

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  6 in total

Review 1.  Tiazofurin: a new antitumor agent.

Authors:  P J O'Dwyer; D D Shoemaker; H N Jayaram; D G Johns; D A Cooney; S Marsoni; L Malspeis; J Plowman; J P Davignon; R D Davis
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

2.  Striking species difference in the contribution of concentrative nucleoside transporter 2 to nucleoside uptake between mouse and rat hepatocytes.

Authors:  Tomomi Furihata; Yukina Fukuchi; Minami Iikura; Misato Hashizume; Atsushi Miyajima; Miki Nagai; Kan Chiba
Journal:  Antimicrob Agents Chemother       Date:  2010-04-26       Impact factor: 5.191

Review 3.  Clinical toxicity associated with tiazofurin.

Authors:  J L Grem; L Rubinstein; S A King; B D Cheson; M J Hawkins; D D Shoemaker
Journal:  Invest New Drugs       Date:  1990-05       Impact factor: 3.850

4.  Phase I and pharmacokinetic study of tiazofurin (TCAR, NSC 286193) administered by continuous infusion.

Authors:  G Batist; R W Klecker; H N Jayaram; J F Jenkins; J Grygiel; D C Ihde; J L Eddy; R L Fine; I G Kerr; J M Collins
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

5.  Clinical pharmacology of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193).

Authors:  R M Green; D J Stewart; J A Maroun
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

6.  Relationships between the cytotoxicity of tiazofurin and its metabolism by cultured human lung cancer cells.

Authors:  D N Carney; G S Ahluwalia; H N Jayaram; D A Cooney; D G Johns
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.